Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take

Bristol-Myers Squibb will pay Halozyme $105 million for the right to use the smaller company ' s technology to develop easier-to-use versions of its best-selling cancer immunotherapy Opdivo, as well as as many as 11 other drugs in the larger company ' s research pipeline.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NYSE:BMY NASDAQ:HALO Source Type: news